Abstract:
본 발명은 하기 화학식 1로 표시되는 신규 페닐아세테이트 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 T-형 칼슘 이온 채널의 활성에 의해 유발되는 질환의 예방 또는 치료용 조성물에 관한 것으로, 본 발명에 따른 페닐아세테이트 유도체를 함유하는 조성물은 T-형 칼슘 이온 채널 활성을 효과적으로 억제하므로 T-형 칼슘 이온 채널의 활성에 의해 유발되는 고혈압, 암, 간질, 신경성 통증 등의 질병의 예방 또는 치료제로서 유용하게 사용될 수 있다. [화학식 1] . (상기 화학식 1에서, 상기 X, R 1 및 R 2 는 본 명세서에서 정의된 바와 같다.) T-형 칼슘 채널 블로커, 페닐아세테이트 유도체, 통증치료제
Abstract:
PURPOSE: A method for preparing 1,6-dioxecane compound is provided to enlarge other ring by Diels-Alder reaction and to use as an intermediate. CONSTITUTION: A 1,6-Dioxecanes compound is denoted by chemical formula 1. The 1,6-Dioxecanes compound is prepared by Prins reaction of alcohol compound of chemical formula 2 and aldehyde compound of chemical formula 3. A tetrahydrofuran is used as a reaction catalyst. The reaction temperature is -78 to 30°C.
Abstract:
PURPOSE: A thiazoline compounds and a T-type calcium channel inhibitor containing the same are provided to treat diseases relating to T-type calcium channel overexpression. CONSTITUTION: A thiazoline compounds have a structure of chemical formula 1. A composition for preventing and treating diseases relating to T-type calcium channel overexpression contains the thiazoline compounds of chemical formula 1. The diseases are Parkinson's disease, Alzheimer, schizophrenia, somnopathy, pain, hypertension, arrhythmia, angina, cardiac insufficiency, myocardial infarction, or cancer.
Abstract:
PURPOSE: A novel phenylacetate derivative and a composition containing the same are provided to suppress T-type calcium ion channel activity and to use as a therapeutic agent for preventing or treating diseases caused by T-type calcium ion channel activity. CONSTITUTION: A phenylacetate derivative is denoted by chemical formula 1. A method for preparing the phenylacetate derivative comprises: a step of performing esterification of a carboxylic acid compound of chemical formula 2 under acid catalyst to obtain an ester compound of chemical formula 3; a step of reacting the compound of chemical formula 3 with t-butoxide and isopropyl bromide to obtain a compound of chemical formula 4; a step of reacting the compound of chemical formula 4 with 1,3-dibromopropane to obtain a compound of chemical formula 5; and a step of reacting the compound of chemical formula 5 with a compound of chemical formula 6 or 7.
Abstract:
본 발명은 1-(2-하이드록시페닐)부타-2-엔-1-온 또는 크로만-4-온 유도체의 제조방법에 관한 것으로서, 더욱 상세하게는 2-에티이닐페놀 유도체를 루이스산 촉매 존재 하에서 알데하이드 화합물과 반응시켜 하기 화학식 1로 표시되는 1-(2-하이드록시페닐)부타-2-엔-1-온 유도체 또는 하기 화학식 2로 표시되는 크로만-4-온 유도체를 제조하는 방법에 관한 것이다.
상기 화학식 1 또는 2에서, R 1 및 R 2 는 각각 발명의 상세한 설명에서 정의한 바와 같다. 1-(2-하이드록시페닐)부타-2-엔-1-온, 크로만-4-온, 루이스산
Abstract:
An N-benzyl-N-(2-dimethylamino-ethyl)benzenesulfonamide compound is provided to show selective antagonistic activity on serotonin 5-HT2a or 5-HT2c receptor and have selective serotonin reuptake inhibitor(SSRI) activity, thereby being used for a pharmaceutical composition for treating and preventing central nervous system diseases. A pharmaceutical composition for treating and preventing diseases such as anxiety, depression, stroke, obsessive neurosis, psychosis, schizophrenia, suicidal tendency, sleep disorders, appetite disorders, withdrawal symptoms caused by drug abuse, and migraine comprises an N-benzyl-N-(2-dimethylamino-ethyl)benzenesulfonamide compound represented by a formula(1) or a pharmaceutically acceptable salt thereof. In the formula(1), R is H, halogen, hydroxy, C1-10 alkyl, C1-10 alkoxy, C1-10 haloalkyl, C1-10 haloalkoxy, C1-10 acyl, phenyl or phenyloxy, provided that a benzen-ring of the phenyl or the phenyloxy may be substituted by H, halogen, cyano, C1-10 alkyl or C1-10 alkoxy.
Abstract:
본 발명은 뇌에서 mPTP의 작용을 선택적으로 억제하여 미토콘드리아의 기능을 향상시키는 신경보호제로서 작용하여 중추신경계 질환의 치료 또는 예방제로 효과를 보이는 유레아 유도체 또는 이의 약제학적으로 허용 가능한 염, 이들 화합물의 제조방법, 그리고 이들 화합물이 유효성분으로 함유된 약학조성물에 관한 것이다.
Abstract:
The present invention relates to thienopyrimidinone derivatives as antagonists that act on metabotropic glutamate receptor subtype 1. The thienopyrimidinone derivatives show pharmacological activity against metabotropic glutamate receptor-related diseases, including pain, such as neuropathic pain and migraine, psychiatric diseases, such as anxiety disorder and schizophrenia, urinary incontinence, and neurodegenerative diseases, such as Parkinson′s disease and Alzheimer′s disease. The present invention also relates to methods for preparing the thienopyrimidinone derivatives, and pharmaceutical compositions containing the thienopyrimidinone derivatives as active ingredients.